CD274 and head and neck squamous cell carcinoma: A turning point in the therapy of HNSCC was the introduction of immunotherapy targeting the programmed death‐1 (PD‐1)/programmed death‐ligand‐1 (PD‐L1) axis, resulting in an improvement in overall survival.6, 7, 8